The Genetics and Neurodegenerative Diseases group aims to identify the main genetic pathways affected in Parkinson's disease and other neurodegenerative disorders. To do this, we will use single-cell RNA sequencing, which will allow us to describe the main genetic alterations with cell-type specificity, using both postmortem brain tissue from patients and cells from peripheral fluid samples donated by patients, as well as tissue from animal models. The data will be validated using histological techniques such as immunofluorescence and in situ hybridization, and spatial transcriptomics techniques such as in situ sequencing. The high sensitivity of the techniques used will allow us to determine the most affected cell types and which genes are most involved, which will guide the exploration of new therapeutic targets and treatment pathways.